2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, B Cell Lymphoma, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4376 Beyond 1 g: A single-infusion 1.5 g low-molecular-weight iron dextran strategy for intravenous iron replacement.

Mark Chaitowitz, MD, Josette Kamel, MD2
1 Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States
2 Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States

Background:

Many adults with iron deficiency anemia (IDA) require replacement doses substantially exceeding 1 g. Yet currently available IV iron formulations generally limit single-infusion dosing to approximately 1g, requiring multiple visits to achieve complete iron replacement. A safe and effective 1.5 g single-infusion regimen could improve convenience, reduce healthcare utilization, and facilitate completion of therapy.

The "Georgetown regimen" established the safety of administering 1 g of low-molecular-weight iron dextran over one hour and has become a de facto standard for total-dose infusion. However, the rationale for limiting single-infusion dosing to 1 g is not well defined, and there is little physiologic rationale to suggest that this dose represents a threshold beyond which toxicity would be expected to increase.

Because infusion-related reactions, including the Fishbane reaction, are thought to relate primarily to infusion rate rather than total iron dose, administration of 1.5 g over two hours represents a conservative extension of this approach. This approach has been adopted at our institution.


Methods:

We retrospectively evaluated consecutive patients treated with 1.5 g of low-molecular-weight iron dextran, administered intravenously over two hours (ID-SDI). Patient characteristics, infusion-related adverse events, and hematological response were assessed.


Results:

From July 2025 through May 2026, ID-SDI was scheduled for 53 patients; 49 completed treatment and were included in the analysis.

Heavy menstrual bleeding accounted for most cases (35/49), 8 had suspected GI blood loss, 2 were pregnant, and in 3 the etiology of IDA was unknown.

Pre-treatment baseline hemoglobin averaged 8.39 ± 1.07 g/dL (range, 6.5–10.9 g/dL), and calculated iron deficits (Ganzoni formula, target Hb 12 g/dl) averaged 1,298 ± 280 mg (range, 739–2,203 mg).

Iron dextran was administered in the usual manner, starting with a 25 mgs test dose, after which the remainder of the 1500 mg was administered over 2 hours.

No serious infusion reactions were reported.

Among 31 patients with at least one Hb measurement within 3 months of infusion, mean Hb increased from 8.16 g/dL at referral to 11.57 g/dL, corresponding to a mean increase of 3.41 ± 1.11 g/dL (range, 1.3–5.7 g/dL). The mean interval from infusion to follow-up hemoglobin assessment was 56.1 ± 18.2 days.

As a descriptive comparison, outcomes were examined in a historical cohort assigned to treatment with ferric carboxymaltose (FCM) 750 mg × 2. Insurance authorization for FCM was denied in 8/66 patients (12%). Forty-four of the 55 authorized patients, (80%) completed both FCM infusions.

Among the 30 patients with follow-up Hb measurements, mean Hb increased from 7.79 to 11.88 g/dL (mean increase 4.09 ± 1.51 g/dL). Follow-up intervals were similar between cohorts (57.3 vs 56.1 days). After adjustment for baseline Hb and follow-up interval, iron formulation was not independently associated with Hb response (β = 0.38 g/dL favoring FCM; 95% CI −0.15 to 0.91; p = 0.15).


Conclusions:

Administration of 1.5 g of low-molecular-weight iron dextran over two hours is well tolerated and effectively corrected iron deficiency in this cohort. Given that many patients require substantially more than 1 g of iron replacement, this regimen represents a pragmatic single-visit alternative to multi-infusion strategies.

A single 1.5 g iron dextran infusion also offers an alternative to ferric carboxymaltose 750 mg × 2, avoiding a second infusion visit, reducing treatment delays associated with insurance authorization, and eliminating the risk of ferric carboxymaltose-associated hypophosphatemia.

These findings support prospective evaluation of higher-dose single-infusion iron dextran regimens with standardized laboratory follow-up, as a means of improving convenience, reducing healthcare utilization, and facilitating complete iron repletion without compromising safety.

Mark Chaitowitz, MD: No relevant conflicts of interest to declare.